Kamau Therapeutics

📍 South San Francisco, United States👥 18 employees💰 Last funded Jan 2025
Biotechnology Research🌐 kamautx.com
Website LinkedIn
Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Kamau Therapeutics?
Kamau Therapeutics has 2 investors on record on gritt.io.
When did Kamau Therapeutics last raise funding?
The most recent investment in Kamau Therapeutics recorded on gritt.io was in January 2025.
What industry is Kamau Therapeutics in?
Kamau Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Kamau Therapeutics based?
Kamau Therapeutics is headquartered in South San Francisco, United States.